Zebrafish data supports new drug candidate moving into human clinical trials
Data Form Part of a Successful Safety and Toxicity Filing to the UK's Regulatory Agency MHRA
Summit has built a capability in testing potential drug compounds using zebrafish. This capability is valuable to drug development companies as it rapidly provides important whole organism data about the safety and toxicity of drug-like molecules and is predictive of effects that might be seen in humans. This technology has the potential to accelerate the discovery process and reduce overall costs relating to drug candidates that might otherwise fail as a result of safety or toxicity issues in later stages of development.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.